CNTG - Centogene N.V.
NASDAQ
->
Healthcare
->
Diagnostics & Research
Rostock,
Germany
Type: Equity
CNTG price evolution
CNTG
| (in millions $) | 31 Jan 2024 | 30 Jul 2023 | 31 Jan 2023 | 30 Oct 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $19.41 | $17.92 | $16.55 | |
| Inventory | $2.46 | $2.13 | $1.82 | |
| Total current assets | $44.02 | $38.91 | $59.83 | |
| Long term investments | ||||
| Property, plant & equipment | $19.28 | $21.61 | $22.16 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $77.16 | $71.89 | $92.81 | |
| Current liabilities | ||||
| Accounts payable | $5.63 | $6.95 | $6.32 | |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $43.37 | $26.9 | $24.66 | |
| Long term debt | $52.28 | $53.09 | $53.18 | |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $102.44 | $87.11 | $85.4 | |
| Shareholders' equity | ||||
| Retained earnings | -$28.76 | -$18.63 | $4.1 | |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $17.82 | $48.16 | ||
| Short term investments | ||||
| Net receivables | $19.41 | $16.55 | $25.32 | $32.2 |
| Inventory | $2.46 | $1.82 | $3.87 | $11.4 |
| Total current assets | $44.02 | $59.83 | $51.48 | $97.05 |
| Long term investments | ||||
| Property, plant & equipment | $19.28 | $22.16 | $27.05 | $38.71 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $60.64 | |||
| Total investments | ||||
| Total assets | $77.16 | $92.81 | $90.69 | $150.13 |
| Current liabilities | ||||
| Accounts payable | $5.63 | $6.32 | $11.25 | $31.74 |
| Deferred revenue | ||||
| Short long term debt | $0.51 | $0.95 | ||
| Total current liabilities | $43.37 | $24.66 | $39.5 | $57.12 |
| Long term debt | $52.28 | $53.18 | $15.59 | $0.4 |
| Total noncurrent liabilities | $31.11 | |||
| Total debt | ||||
| Total liabilities | $102.44 | $85.4 | $63.19 | $84.35 |
| Shareholders' equity | ||||
| Retained earnings | -$28.76 | $4.1 | -$109.3 | -$62.84 |
| Other shareholder equity | $27.23 | $18.37 | ||
| Total shareholder equity | $27.31 | $65.68 | ||
| (in millions $) | 31 Jan 2024 | 30 Jul 2023 | 31 Jan 2023 | 30 Oct 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $48.54 | $24.62 | ||
| Cost of revenue | ||||
| Gross Profit | $17.7 | $9.39 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $46.1 | $29.65 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.29 | $0.01 | ||
| Interest expense | -$5.43 | -$2.75 | ||
| Net income | ||||
| Net income | -$35.53 | -$24.46 | ||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $48.54 | $128.38 | ||
| Cost of revenue | $81.68 | |||
| Gross Profit | $17.7 | $46.7 | ||
| Operating activities | ||||
| Research & development | $14.94 | |||
| Selling, general & administrative | $45.24 | |||
| Total operating expenses | $45.72 | $139.54 | ||
| Operating income | -$11.16 | |||
| Income from continuing operations | ||||
| EBIT | -$11.16 | |||
| Income tax expense | $0.29 | $0.28 | ||
| Interest expense | -$5.99 | -$0.17 | ||
| Net income | ||||
| Net income | -$35.53 | -$21.38 | ||
| Income (for common shares) | -$21.38 | |||
| (in millions $) | 31 Jan 2024 | 30 Jul 2023 | 31 Jan 2023 | 30 Jul 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $2.28 | -$2.14 | -$0.73 | -$0.21 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $13.04 | -$5.19 | $46.32 | $31.06 |
| Effect of exchange rate | -$0.42 | $0.02 | -$0.96 | |
| Change in cash and equivalents | -$16.85 | -$21.8 | $18.13 | $15.7 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | -$46.85 | -$21.38 | ||
| Operating activities | ||||
| Depreciation | $17.15 | $7.27 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$21.74 | $8.46 | ||
| Investing activities | ||||
| Capital expenditures | -$2.92 | -$9.89 | ||
| Investments | ||||
| Total cash flows from investing | $2.28 | -$0.73 | -$5.36 | -$16.15 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$2.94 | -$7.34 | ||
| Total cash flows from financing | $13.04 | $46.32 | -$3.2 | $14.84 |
| Effect of exchange rate | -$0.42 | -$0.96 | -$0.04 | -$0.09 |
| Change in cash and equivalents | -$16.85 | $18.13 | -$30.34 | $7.06 |
News
Fundamentals
| Market cap | $3.77M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 29.00M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 333.43% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.02 |
| Quick ratio | 0.96 |